Navigation Links
Positive Clinical Study Results for BSP's HyperQ Technology

TEL-AVIV, Israel, November 14, 2011 /PRNewswire/ --

BSP Biological Signal Processing Ltd. (BSP) (TASE: BSP), which develops and manufactures products for the non-invasive, accurate diagnosis of Coronary Artery Disease (CAD), recently announced the successful completion of a comprehensive clinical research study evaluating the performance of the company's HyperQ technology in diagnosing CAD. An article describing the study and its results was accepted for publication in the prestigious American Journal of Cardiology.

The study recruited 996 patients and compared the clinical performance of HyperQ vs. conventional ECG for the detection of Coronary Artery Disease (CAD), using nuclear imaging as the gold standard. The study was conducted in two major medical centers in Israel - Assuta Medical Center and Sheba Medical Center, and was headed by Dr. Tali Sharir and Prof. Pierre Chouraqui.  The major finding reported by the researchers is a 30% improvement in the sensitivity of the HyperQ analysis in the detection of CAD when compared to conventional stress ECG. HyperQ analysis also had a lower false alarm rate compared to conventional stress ECG.

"This comprehensive study significantly deepens clinical knowledge accumulated so far by our company and substantiates the evidence that HyperQ improves the ability to diagnose ischemic heart disease," says Nissim Greisas, CEO of BSP.  He added, "We believe that the results of this study will have a major impact on the decision of cardiologists to clinically implement the use of HyperQ products in their routine workup for diagnosing and assessing ischemic heart disease."

The results of this study were also recently presented, together with additional HyperQ related clinical evidence, at a meeting and hearing of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) in the US. The MEDCAC meeting on November 9th was convened in order to consider and make recommendations on the use of new ECG signal analysis technologies to detect CAD, and regarding their inclusion in the coverage policies.  MEDCAC is an advisory committee, commissioned by to CMS (Centers for Medicare & Medicaid Services) - the organization responsible for the determination of the services and medical products that will be reimbursed by Medicare and Medicaid, also heavily weighing in on the coverage policies of private insurers in the US. The MEDCAC committee concluded its discussions with a recommendation encouraging the CMS to include new signal analysis technologies, that are FDA cleared and have shown sufficient clinical evidence, in the coverage policies for cardiac care and diagnosis.

"Appearing before MEDCAC committee is an important milestone in the process of obtaining reimbursement for our products in the U.S.," says Dr. Amir Beker, Chairman of BSP, who presented at the hearing. He added, "This endeavor is also backed by a HyperQ large-scale clinical study in three leading US medical centers, The Cleveland Clinic, University of Virginia medical center and Minneapolis Heart Institute Foundation, to collect clinical and economic data in support of BSP's reimbursement campaign in the US".

About Biological Signal Processing Ltd.  

Founded in 2000, BSP develops the most accurate stress ECG equipment for diagnosing Coronary Artery Disease (CAD) for men and women. HyperQ, BSP's proprietary signal processing technology, focuses on a brand new component of the ECG signal, significantly improving the accuracy of the stress ECG test and making HyperQ technology- the new standard for the early detection of coronary artery disease.  BSP is a public company, traded on the Tel Aviv Stock Exchange since 2006 (TASE: BSP). The company's headquarters are located in Tel Aviv, Israel with offices in Boston, US.


For further information, please contact , +972-3-647-4840


SOURCE BSP - Biological Signal Processing Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women
3. Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program
4. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
5. NORTHWEST BIO Announces Positive Third Quarter Progress
6. Otonomy Presents Positive New Findings From Phase 1b Study of OTO-104 in Menieres Disease at International Conference
7. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
8. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
9. Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad
10. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
11. Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
Post Your Comments:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology:
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):